Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Seliger

Showing results (171-180 of 304) with videos related to

Pageof 31
Sort By:
Proteomics|December 7, 2002
Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significanceRoland Kellner, Rudolf Lichtenfels, Derek Atkins, et al.
Cancer Immunology, Immunotherapy : CII|October 13, 2009
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancerBarbara Seliger, Robert Stoehr, Diana Handke, et al.
Oncotarget|October 22, 2015
VHL-dependent alterations in the secretome of renal cell carcinoma: Association with immune cell response?Franziska Stehle, Sandra Leisz, Kristin Schulz, et al.
Oncoimmunology|March 5, 2016
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosisEmilia Andersson, Isabel Poschke, Lisa Villabona, et al.
European Journal of Medicinal Chemistry|December 3, 2014
Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogensClaudia Bobach, Stephanie Tennstedt, Kristin Palberg, et al.
Cancer Immunology, Immunotherapy : CII|January 20, 2012
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancerEmilia Andersson, Lisa Villabona, Kjell Bergfeldt, et al.
Journal of Translational Medicine|November 13, 2025
Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGFβ axis and immune suppression in aggressive thyroid cancerMario Udinotti, Udo Siebolts, Marcus Bauer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 6, 2024
Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survivalJulia Ohlinger, Dirk Vordermark, Christian Ostheimer, et al.
Oncotarget|July 14, 2016
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localizationAndré Steven, Sandra Leisz, Katharina Sychra, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 9, 2021
What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the pastYu Yao, Heng Liang, Xin Fang, et al.
Pageof 31

Showing results (171-180 of 304) with videos related to

Sort By:
Pageof 31
Proteomics|December 7, 2002
Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significanceRoland Kellner, Rudolf Lichtenfels, Derek Atkins, et al.
Cancer Immunology, Immunotherapy : CII|October 13, 2009
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancerBarbara Seliger, Robert Stoehr, Diana Handke, et al.
Oncotarget|October 22, 2015
VHL-dependent alterations in the secretome of renal cell carcinoma: Association with immune cell response?Franziska Stehle, Sandra Leisz, Kristin Schulz, et al.
Oncoimmunology|March 5, 2016
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosisEmilia Andersson, Isabel Poschke, Lisa Villabona, et al.
European Journal of Medicinal Chemistry|December 3, 2014
Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogensClaudia Bobach, Stephanie Tennstedt, Kristin Palberg, et al.
Cancer Immunology, Immunotherapy : CII|January 20, 2012
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancerEmilia Andersson, Lisa Villabona, Kjell Bergfeldt, et al.
Journal of Translational Medicine|November 13, 2025
Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGFβ axis and immune suppression in aggressive thyroid cancerMario Udinotti, Udo Siebolts, Marcus Bauer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 6, 2024
Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survivalJulia Ohlinger, Dirk Vordermark, Christian Ostheimer, et al.
Oncotarget|July 14, 2016
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localizationAndré Steven, Sandra Leisz, Katharina Sychra, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 9, 2021
What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the pastYu Yao, Heng Liang, Xin Fang, et al.
Pageof 31